argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares.
argenx raises $1.1 billion in gross proceeds in a global offering Read More »
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a Clinical Trial Application to initiate a Phase 1/2 clinical trial of OTOF-GT in Europe.
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody -associated vasculitis.
Biophytis SA announced that it has entered into definitive agreements for the purchase and sale of 1,333,334 units, each consisting of one American Depositary Share or one prefunded warrant giving right to one ADS and one warrant to purchase one ADS, at a purchase price of $2.85 per unit comprising an ADS and $2.84 per
Biophytis Announces $3.8 Million Registered Direct Offering Read More »
RELIEF THERAPEUTICS Holding SA announced an extension of its exclusive, long-term agreement with Pentec Health, Inc., broadening the distribution of PKU GOLIKE® in the U.S. Pentec Health is a leading provider of healthcare services for complex care challenges, including clinical nutrition and specialty care, and the exclusive distributor of PKU GOLIKE® in the U.S.
Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS) today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share.
Acumen Announces Pricing of Upsized $130 Million Public Offering Read More »
Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), announced today that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a. It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.
The implantable defibrillators may fail to deliver an electric shock to restore normal heart rhythm when needed, which could lead to a serious injury or death, the FDA said.
Medtronic recalls nearly 350,000 defibrillators for risk of reduced shock Read More »
Una investigación reciente centrada en el Golfo de Cádiz y el Mar de Alborán ha expuesto las conexiones entre las presiones humanas, la pérdida de biodiversidad, la prestación de servicios ecosistémicos y las estrategias de conservación y gestió …
Deterioro sostenido de ecosistemas marinos al sur de España Read More »
Medio año después de su despegue, el nanosatélite Menut, la segunda misión satelitaria y la primera de observación de la Tierra de la Estrategia NewSpace de Cataluña impulsada por la Generalitat de Cataluña, ya recolecta datos para contribuir a mejora …
